Clinical trial · Interventional
An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients With Advanced Liver Cancer
Multiparametric MRI and MRE Assessment of Liver Fibrosis in Patients Treated for HCC
NCT04022746CI-TRIAL-00086179completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This trial studies how well an investigational scan (magnetic resonance elastography \[MRE\]) works with standard imaging (magnetic resonance imaging \[MRI\]) in detecting response to treatment in patients with liver cancer that has spread to other places in the body. Diagnostic procedures, such as MRE with MRI, may make it easier for researchers to see if the treatment for liver cancer is working.
Conditions
Conditions (7)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Adult Hepatocellular Carcinoma | Adult Hepatocellular Carcinoma | CURATED_BROADER | 0.78 |
| Stage IIIA Hepatocellular Carcinoma AJCC v8 | Hepatocellular Carcinoma | CURATED_BROADER | 0.78 |
| Stage IIIB Hepatocellular Carcinoma AJCC v8 | Hepatocellular Carcinoma | CURATED_BROADER | 0.78 |
| Stage III Hepatocellular Carcinoma AJCC v8 | Hepatocellular Carcinoma | CURATED_BROADER | 0.78 |
| Stage IVA Hepatocellular Carcinoma AJCC v8 | Hepatocellular Carcinoma | CURATED_BROADER | 0.78 |
| Stage IVB Hepatocellular Carcinoma AJCC v8 | Hepatocellular Carcinoma | CURATED_BROADER | 0.78 |
| Stage IV Hepatocellular Carcinoma AJCC v8 | Hepatocellular Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Magnetic Resonance Elastography | Procedure | — | UNRESOLVED |
| Magnetic Resonance Imaging | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Diagnostic (MRI/MRE)
- description
- Patients undergo standard of care MRI and MRE over 30-90 minutes within 5 days of liver biopsy before receiving any medical treatment for HCC, at 6 weeks after medical treatment for HCC, and then every 12 weeks for up to 24 months.
- interventionNames
- Procedure: Magnetic Resonance Elastography
- Procedure: Magnetic Resonance Imaging
Primary outcomes (2)
- measure
- Change in magnetic resonance elastography (MRE) liver tumor stiffness
- timeFrame
- Baseline to 6 weeks
- description
- Imaging measurements and percent necrosis will be summarized using mean, standard deviation (SD), and range. Pearson correlation coefficient will be estimated between imaging measurements and percent necrosis.
- measure
- Change in percent non-viable/necrotic tumor
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Liver cancer. * Available tumor and liver parenchyma tissue (biopsy-proven HCC). * No contraindications to MRI (such implanted ferromagnetic or pump devices, metallic fragments in eye), as indicated on our departmental MRI screening form. * Able to undergo informed consent. * Not pregnant. Exclusion Criteria: * Contraindication to MRI (including cardiac pacemaker; ferromagnetic foreign objects in the patient; metallic eye fragments; claustrophobia). * Inability to comply with study and/or follow-up procedures.
References
Publications (0)
Data not yet available
No reference posted for this study.